Floatz logo

Empagliflozin

NAFLD

Justin RyderSmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
89/ 100

Competitive context

139 Active assets in the NAFLD cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Tirzepatide
Regeneron Pharmaceuticals
Phase 3BBB

View all 50 →

Same molecule, other indications

Empagliflozin is also rated in:

Hypoglycemic AgentsDormant
BBB
Indicative ·
75 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
74 / 100
View asset →
Physiological Effects of DrugsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →